V F 4 Years N Recovered DT FEVER INJECTION SITE REACTION
|
|
- Hilary Robertson
- 5 years ago
- Views:
Transcription
1 * CAVEAT: The vast majority of reports on which this summary is based are submitted by health practitioners. Each report represents the suspicion, opinion or observation of the individual reporter. Cause and effect relationships have not been established in the vast majority of reports submitted. The information contained in these reports to Population and Public Health Branch has not been reviewd as to cause and effect relationship by Population and Public Health Branch scientists. Only a small portion of suspected adverse reactions are reported to the program, consequently this information must not be used to estimate the incidence of adverse events. Reports submitted by pharmaceutical manufacturers are included in this summary. This summary contains unpublished data and is provide to you with the understanding that this data will be used only for your personal use or within your immediate organization. Vaccine: DTP (n=49); DT 274-1A (n=0); IPV (n=8); HIB K0442 (n=9); DT (n=12); HIB V0204 (n=0); (N=0); HIB K0827 (N=29); DT (n=3) IPV (n=6); IPV (n=0); MMR C (n=25) Date Id Received Sex Age Age Unit Hosp Outcome Vaccine Lot # Reaction V F 4 Years N Recovered DT FEVER INJECTION SITE REACTION V F 5 Years N Recovered DT FEVER IPV SEVERE PAIN AND/OR SWELLING V M 5 Years N Recovered DT FEVER V F 5 Years Recovered DT FEVER - TEMPERATURE NOT RECORDED IPV SEVERE PAIN AND/OR SWELLING ALLERGIC REACTION V M 2 Years N DT SEVERE PAIN AND/OR SWELLING IPV V F 6 Years N Recovered DT INJECTION SITE REACTION V F 2 Years N Recovered DT FEVER HIBAC K0399 IPV V F 5 Years N Recovered DT FEVER STERILE ABCESS/NODULE/NECROSIS V F 5 Years N Recovered DT ARTHRALGIA/ARTHRITIS V M 1 Years N Recovered IPV SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE DT V F 3 Years N Recovered DT SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE ALLERGIC REACTION - SKIN
2 V F 4 Years Recovered DT SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE APATHY DIARRHOEA PALLOR INJECTION SITE BRUISING V F 2 Years N Recovered DT FEVER V F 4 Years Recovered with Sequalae DT SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE V M 4 Years Recovered DT SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE V M 2 Months N Recovered HIBTI 3A0896 SCREAMING EPISODE/PERSISTENT CRYING V M 4 Months Y Recovered HIBTI 2M0279 HYPOTONIC-HYPORESPONSIVE EPISODE SOMNOLENCE DYSPNOEA V M 4 Years N Recovered FEVER - TEMPERATURE NOT RECORDED HYPOTONIC-HYPORESPONSIVE EPISODE V F 3 Months N Recovered HIBTI 3E0465 FEVER V M 4 Years N FEVER - TEMPERATURE NOT RECORDED HALLUCINATION V F 2 Months N Recovered HYPOTONIC-HYPORESPONSIVE EPISODE V F 2 Months N Recovered SCREAMING EPISODE/PERSISTENT CRYING V M 3 Months N HIBTI 2M0278 FEVER V M 6 Years N ALLERGIC REACTION V M 7 Months N HIBTI 3E0466 ALLERGIC REACTION RASHES V M 18 Months N Recovered HIBTI - HYPOTONIC-HYPORESPONSIVE EPISODE
3 V M 18 Months N Recovered V M 1 Years N Recovered HIBTI 3E0468 FEVER FEVER - TEMPERATURE NOT RECORDED SEVERE PAIN AND/OR SWELLING V F 2 Years N Recovered FEVER SEVERE PAIN AND/OR SWELLING ADENOPATHY V M 5 Months N FEVER >= 40.5 RASHES SCREAMING EPISODE/PERSISTENT CRYING V M 5 Years N FEVER V F 3 Months N Recovered HIBTI 3A0896 FEVER V M 2 Months N HIBTI 3F0617 FEVER - TEMPERATURE NOT RECORDED V F 1 Years N HIBTI 2M0834 FEVER >= 40.5 V M 1 Years N HIBTI 2M0834 STERILE ABCESS/NODULE/NECROSIS V F 5 Months N HIBTI 3J0158 FEVER V M 1 Months N HIBTI - SEVERE PAIN AND/OR SWELLING V M 6 Months N HIBTI 3F0385 SCREAMING EPISODE/PERSISTENT CRYING V M 5 Years N SEVERE PAIN AND/OR SWELLING V M 5 Years N SEVERE PAIN AND/OR SWELLING V Years N Recovered STERILE ABCESS/NODULE/NECROSIS
4 V M 1 Years N Recovered FEVER - TEMPERATURE NOT RECORDED SCREAMING EPISODE/PERSISTENT CRYING V M 5 Months N Recovered FEVER SCREAMING EPISODE/PERSISTENT CRYING V M 1 Years N Recovered HIBTI 3F0385 CONVULSION/SEIZURE V M 2 Months N HIBTI 3E0466 FEVER >= 40.5 SCREAMING EPISODE/PERSISTENT CRYING V F 6 Months N Recovered FEVER HIBAC - HYPOTONIC-HYPORESPONSIVE EPISODE CONVULSION/SEIZURE V M 3 Months N HIBTI 3F0385 RASHES V F 4 Years N SEVERE PAIN AND/OR SWELLING V F 4 Months N Recovered HIBTI 3E0465 FEVER - TEMPERATURE NOT RECORDED SCREAMING EPISODE/PERSISTENT CRYING OPISTHOTONOS INSOMNIA V M 4 Months N HIBTI 2M0834 V M 1 Years N FEVER - TEMPERATURE NOT RECORDED HYPOTONIC-HYPORESPONSIVE EPISODE V M 2 Months N HIBTI 3C0629 FEVER - TEMPERATURE NOT RECORDED SEVERE PAIN AND/OR SWELLING SCREAMING EPISODE/PERSISTENT CRYING V F 1 Months N HIBTI 3E0466 FEVER >= 40.5 SEVERE PAIN AND/OR SWELLING SCREAMING EPISODE/PERSISTENT CRYING V M 2 Months N Recovered HIBTI 3F0617 HYPOTONIC-HYPORESPONSIVE EPISODE
5 V F 2 Months N Recovered HIBTI 3F0777 FEVER >= 40.5 V F 5 Years N ARTHRALGIA/ARTHRITIS V M 2 Months N SEVERE PAIN AND/OR SWELLING SCREAMING EPISODE/PERSISTENT CRYING V F 4 Months N HIBTI 3A0896 V M 2 Months N Recovered HIBTI 3E0468 FEVER SCREAMING EPISODE/PERSISTENT CRYING V F 2 Months N Recovered HYPOTONIC-HYPORESPONSIVE EPISODE HIBAC - V M 3 Months N HIBTI 3C0629 HYPOTONIC-HYPORESPONSIVE EPISODE V M 8 Months Y Fatal HIBTI 3K0639 FEVER >= 40.5 BRADYCARDIA V F 2 Months N Recovered HIBAC L1008 SEVERE PAIN AND/OR SWELLING V M 2 Months N Recovered HIBAC K0442 INJECTION SITE REACTION DPTP V M 5 Years Recovered SEVERE PAIN AND/OR SWELLING V M 4 Months N Recovered DPTP INJECTION SITE REACTION HIBAC K0442 V M 7 Months N Recovered HIBAC K0442 ALLERGIC REACTION - SKIN DPTP V F 1 Years N Recovered HIBAC K0442 FEVER >= 40.5 P IPV V F 5 Months Y Recovered DPTP FEVER - TEMPERATURE NOT RECORDED HIBAC K0442 SEVERE PAIN AND/OR SWELLING
6 INJECTION SITE ABSCESS SEPSIS V M 1 Years N Recovered MMR - FEVER >= 40.5 DPTP HIBAC K0442 V M 4 Months N DPTP FEVER - TEMPERATURE NOT RECORDED HIBAC K0442 SEVERE PAIN AND/OR SWELLING RASHES SCREAMING EPISODE/PERSISTENT CRYING V M 6 Months N Recovered HIBAC K0442 INJECTION SITE REACTION DPTP V F 1 Years N Recovered HIBAC K0442 FEVER DPTP HYPOTONIC-HYPORESPONSIVE EPISODE V F 2 Years N Recovered DT FEVER HIBAC K0399 IPV V F 5 Years N Recovered MR OEDEMA IPV DT V M 4 Years N Recovered DT OEDEMA IPV V M 4 Years N Recovered IPV FEVER SKELETAL PAIN HEADACHE TREMOR ABDOMINAL PAIN V M 11 Months N Recovered IPV HIBAC K0827 SOMNOLENCE V M 3 Months Recovered DT FEVER >= 40.5 IPV
7 V M 49 Years Recovering HA 163A4 SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE & PAS IPV ADENOPATHY - ENLARGED LYMPHNODES BACK PAIN MALAISE INJECTION SITE REACTION V F 22 Years N Recovered IG C7R01A MYALGIA IPV FATIGUE MALAISE V F 5 Years N Recovered IPV SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE T V M N Recovered HIBAC K0827 FEVER IPV INJECTION SITE REACTION P V F 22 Years N Recovering TYPH-O A FEVER - TEMPERATURE NOT RECORDED IPV SEVERE PAIN AND/OR SWELLING - PAST JOINTS RAB SKELETAL PAIN MOUTH DRY ABDOMINAL PAIN RIGORS V F 19 Years N Recovered IPV ALLERGIC REACTION - SKIN PPD-T V F 15 Years N Recovered IPV SEVERE PAIN AND/OR SWELLING V M 5 Years Recovered P INJECTION SITE INFLAMMATION IPV MMR W1173 V F 4 Years SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE & PAS DPTP SKELETAL PAIN HYPOKINESIA V M 25 Years Recovered Td 2DT19011 SEVERE PAIN AND/OR SWELLING ADENOPATHY INJECTION SITE REACTION V M 5 Years FEVER >= 40.5
8 V M 6 Years N Recovered DPTP INSOMNIA DYSPNOEA PALLOR MALAISE SEVERE PAIN AND/OR SWELLING SKELETAL PAIN DIZZINESS HEADACHE VOMITING INJECTION SITE PAIN V F 4 Years N INJECTION SITE INFLAMMATION DPTP V F 4 Years N Recovered DPTP FEVER >= 40.5 V F 4 Years N Recovered ALLERGIC REACTION - SKIN DPTP V F 1 Years Recovered FEVER >= 40.5 RASHES APATHY PHARYNGITIS V F 5 Years Recovered FEVER CONVULSION/SEIZURE - FEBRILE V M 4 Years Y Recovering FEVER - TEMPERATURE NOT RECORDED DPTP RASHES MENINGITIS AND/OR ENCEPHALITIS SOMNOLENCE V Years Recovered ALLERGIC REACTION - RESPIRATORY & SKIN DPTP - V M 1 Years N ALLERGIC REACTION V F 5 Years Recovered FEVER >= 40.5 DPTP SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE MALAISE
9 V F 4 Years FEVER - TEMPERATURE NOT RECORDED DPTP SCREAMING EPISODE/PERSISTENT CRYING NAUSEA PALLOR INJECTION SITE PAIN V F 21 Years N Recovered INJECTION SITE REACTION V M 13 Years N Recovered SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE OEDEMA V M 4 Years N Recovered FEVER DPTP INJECTION SITE REACTION V F 5 Years DPTP FEVER - TEMPERATURE NOT RECORDED SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE V F 1 Years Y Recovered FEVER ALLERGIC REACTION - SKIN URTICARIA SOMNOLENCE CYANOSIS TACHYCARDIA DYSPNOEA V F 35 Years N ARTHRALGIA/ARTHRITIS V M 1 Years N FEVER V F 1 Years N RASHES V F 1 Years Recovering FEVER >= 40.5 RASHES - GENERALIZED CONVULSION/SEIZURE - FEBRILE CRYING ABNORMAL V F 4 Years Y Recovering DPTP PTOSIS V F 5 Years N DPTP SEVERE PAIN AND/OR SWELLING V F 1 Years N RASHES - GENERALIZED
10 CONJUNCTIVITIS V M 4 Years N Recovered DPTP ALLERGIC REACTION - SKIN V M 5 Years Recovered ALLERGIC REACTION - RESPIRATORY & SKIN DPTP V F 4 Years Y Recovered DPTP ANAPHYLAXIS V F 5 Years N DPTP STERILE ABCESS/NODULE/NECROSIS V F 1 Years N ALLERGIC REACTION V M 1 Years N ALLERGIC REACTION V M 1 Years N DPTP ALLERGIC REACTION HIBAC L0558 V F 4 Years N DPTP HEADACHE INJECTION SITE INFLAMMATION V F 1 Years N CONVULSION/SEIZURE V M 1 Years N DPTP SEVERE PAIN AND/OR SWELLING HIBAC L0596 V N Recovered FEVER ADENOPATHY RASHES - GENERALIZED PAROTITIS PRURITUS SOMNOLENCE V F 1 Years N Recovered FEVER - TEMPERATURE NOT RECORDED
11 V F 4 Years N Recovered DPTP FEVER - TEMPERATURE NOT RECORDED SOMNOLENCE V M 1 Years N FEVER SCREAMING EPISODE/PERSISTENT CRYING V M 1 Years N FEVER CONVULSION/SEIZURE V M 1 Years FEVER - TEMPERATURE NOT RECORDED CONVULSION/SEIZURE - AFEBRILE V F 5 Years Recovered DPTP SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE RASHES - LOCALIZED OEDEMA V M 4 Years N Recovered DPTP SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE V M 4 Years N DPTP FEVER - TEMPERATURE NOT RECORDED STERILE ABCESS/NODULE/NECROSIS V F 5 Years N Recovered DPTP FEVER - TEMPERATURE NOT RECORDED DIZZINESS DIARRHOEA PALLOR MALAISE V M 5 Years N Recovered RASH DPTP INJECTION SITE REACTION V M 5 Years N Recovered IPV FEVER DT SEVERE PAIN AND/OR SWELLING - PAST JOINTS OEDEMA V F 1 Years N FEVER RASHES V M 1 Years N RASHES V F 1 Years N DPTP FEVER HIBAC L0597 RASHES
12 V F 1 Years Y Recovered FEVER RASHES CONVULSION/SEIZURE - FEBRILE V M 5 Years N Recovered FEVER - TEMPERATURE NOT RECORDED SEVERE PAIN AND/OR SWELLING - PAST JOINTS SOMNOLENCE V F 1 Years N Recovered DPTP FEVER - TEMPERATURE NOT RECORDED HIBAC L1008 RASH V M 2 Years N Recovered HIBAC L1008 FEVER - TEMPERATURE NOT RECORDED DPTP V F 1 Years N ARTHRALGIA/ARTHRITIS V F 4 Years Recovered DPTP FEVER >= 40.5 SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE HEADACHE NAUSEA V F 4 Years N Recovered DPTP FEVER >= 40.5 SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE V F 1 Years FEVER >= 40.5 INJECTION SITE REACTION V F 4 Years Recovered DPTP FEVER >= 40.5 SEVERE PAIN AND/OR SWELLING - PAST JOINTS RASHES - LOCALIZED ARTHRALGIA/ARTHRITIS PAROTITIS MYALGIA HEADACHE ANOREXIA ABDOMINAL PAIN COUGHING V M 5 Years Recovered DPTP FEVER INJECTION SITE INFLAMMATION
13 V F 4 Years N Recovered SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE DPTP V F 6 Years N Recovered FEVER SEVERE PAIN AND/OR SWELLING V F 5 Years N Recovered DPTP FEVER - TEMPERATURE NOT RECORDED HIBAC - SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE VOMITING NAUSEA V F 4 Years N DPTP ALLERGIC REACTION - SKIN V F 4 Years Recovered DTP FEVER - TEMPERATURE NOT RECORDED ALLERGIC REACTION - SKIN ARTHRALGIA/ARTHRITIS V M 5 Years N Recovered DPTP ALLERGIC REACTION - RESPIRATORY & SKIN V M 13 Months Recovered MMR C RASHES - LOCALIZED V F 1 Years Y Recovered MMR C FEVER JAUNDICE V F 2 Years Y Recovered MMR C CONVULSION/SEIZURE - AFEBRILE DaPTP - HIBAC P0101 V M 1 Years N Recovered with Sequalae MMR C SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE DaPTP - HIBAC N0581 V M 1 Years N Recovered MMR C RASH V F 13 Months Y Recovered MMR C FEVER V M 18 Months Recovered MMR C RASHES - GENERALIZED DaPTP -
14 HIBAC P0065 V F 37 Years Recovered MMR C CELLULITIS DaPTP V M 1 Years Recovered DaPTP - RASH HIBAC P0196 INSOMNIA MMR C INJECTION SITE REACTION V F 1 Years Recovered MMR C SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE DaPTP - HAEMATOMA HIBAC P0196 V M 1 Years Recovered with Sequalae DaPTP - SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE & PAS HIBAC P0464 INJECTION SITE BRUISING MMR C V M 5 Years Recovered MMR C FEVER DaPTP SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE & PAS DIZZINESS APATHY FATIGUE V M 1 Days Recovered DaPTP C STERILE ABCESS/NODULE/NECROSIS HIBAC P0366 PAROTITIS MMR C FEVER V M 2 Years Recovered MMR C11320 FEVER - TEMPERATURE NOT RECORDED MUSCLE CONTRACTIONS INVOLUNTARY SOMNOLENCE ANOREXIA V M 1 Years Recovered DaPTP - FEVER HIBAC P0588 RASHES MMR C SOMNOLENCE ANOREXIA FATIGUE V M 31 Years Unknown TdP FEVER MMR C INJECTION SITE INFLAMMATION
15 FLU-S 3FV58F11 V F 28 Years Recovered YF 6906-B SEVERE PAIN AND/OR SWELLING - 4 DAYS OR MORE MMR C ARTHRALGIA/ARTHRITIS PRURITUS V M 4 Years Unknown DaPTP FEVER >= 40.5 MMR C ARTHRALGIA/ARTHRITIS PAROTITIS SOMNOLENCE V F 40 Years Recovered MMR C RASH YF 7044-A V F 4 Years Unknown MMR C ALLERGIC REACTION - SKIN DaPTP V F 1 Years Y Unknown DaPTP - THROMBOCYTOPENIA HIBAC P0467 MMR C V M 1 Years Recovered MMR C RASHES COUGHING FEVER V F 1 Years Recovered MMR C FEVER ANOREXIA V F 1 Years Recovered MMR C FEVER - TEMPERATURE NOT RECORDED V M 18 Months Recovered MMR C RASH V M 18 Months Recovered MMR C SEVERE PAIN AND/OR SWELLING - PAST JOINTS DaPTP - HIBAC P1329 V F 2 Years Y Recovered MMR C CONVULSION/SEIZURE - AFEBRILE DaPTP - HIBAC P0101 V F 14 Months Y Recovered MMR C FEVER RASH
16
Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines
Adverse events following immunisation (AEFI) with 00/0 seasonal influenza vaccines Netherlands Pharmacovigilance Centre Lareb 8 juli 0 Goudsbloemvallei 7 57 MH s-hertogenbosch www.lareb.nl info@lareb.nl
More informationBOOSTRIX. Combined diphtheria, tetanus, acellular pertussis vaccine
BOOSTRIX Combined diphtheria, tetanus, acellular pertussis vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml) contains: Diphtheria toxoid 1 Tetanus toxoid 1 Bordetella pertussis antigens
More informationIMMUNIZATION REGULATION
Province of Alberta PUBLIC HEALTH ACT IMMUNIZATION REGULATION Alberta Regulation 182/2018 Extract Published by Alberta Queen s Printer Alberta Queen s Printer Suite 700, Park Plaza 10611-98 Avenue Edmonton,
More informationIMOJEV Japanese encephalitis vaccine (live, attenuated)
IMOJEV Japanese encephalitis vaccine (live, attenuated) Consumer Medicine Information What is in this leaflet Read all of this leaflet carefully before you or your child is vaccinated. Keep this leaflet.
More informationBOOSTRIX QUALITATIVE AND QUANTITATIVE COMPOSITION PHARMACEUTICAL FORM CLINICAL PARTICULARS. Indications. Dosage and Administration
BOOSTRIX Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content) QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml) contains: Diphtheria toxoid 1 Tetanus
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationCase Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014
- 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases
More informationSummary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015
Page 1 of 6 Adverse (s) Date Outcome 2014-019844 04/03/2014 13 Years Prophylaxis GARDASIL 04/12/2013 Nausea 04/12/2013 06/12/2013 Headache 04/12/2013 06/12/2013 Vomiting 04/12/2013 06/12/2013 Asthenia
More informationLondon, 24 January 2000 EMEA/1952/00
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 24 January 2000 EMEA/1952/00 EMEA PUBLIC STATEMENT ON ABACAVIR (Ziagen) IMPORTANT SAFETY INFORMATION
More informationSECTION IX VACCINE ASSOCIATED ADVERSE EVENTS TABLE OF CONTENTS
SECTION IX VACCINE ASSOCIATED ADVERSE EVENTS TABLE OF CONTENTS INTRODUCTION... 1 PURPOSE... 1 FORMAT... 2 1.0 FEVER... 3 2.0 LOCAL REACTION AT INJECTION SITE... 4 2.1 Minor... 4 2.2 Major (Arthus-reaction)...
More informationLessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring
Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring ENCePP Plenary meeting Xavier Kurz 8 June 20 An agency of the European Union Contents 1. Safety database at time of authorisation
More informationINVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests
Minor Allergic (Urticarial) Urticaria, pruritis, flushing, rash If skin reaction only and mild hives/ rash
More informationVaccine safety messages
Vaccine safety messages This document is intended to support immunization programme managers and staff in their efforts to secure sustainable funding for immunization. HOW TO USE THIS DOCUMENT Many people
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Tetravac, suspension for injection Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine, adsorbed.
More informationSummary of adverse drug reaction reports in Sweden with Pandemrix (received up to...
Page 1 sur 5 Home / All news / Summary of adverse drug reaction reports in Sweden with Pandemrix (received up to November 10) Thursday, November 12, 2009 As of today, about 2.1 million doses of Pandemrix
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Pre-filled syringe: IPV-Boostrix suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component)
More informationUpdate on safety of pandemic influenza A (H1N1) vaccines
Update on safety of pandemic influenza A (H1N1) vaccines Dr David Wood Department of Immunization Vaccines and Biologicals Quality, safety and standards SAGE 28 October 2009 Context of vaccine safety discussions
More informationManagement of an immediate adverse event following immunisation
Management of an immediate adverse event following immunisation The vaccinated person should remain under observation for a short interval to ensure that they do not experience an immediate adverse event.
More informationCLINICAL PHARMACOLOGY INFANRIX DTPa vaccine, induces antibodies against all vaccine components.
INFANRIX PRODUCT INFORMATION NAME OF THE MEDICINE Diphtheria-tetanus-acellular pertussis (DTPa) vaccine DESCRIPTION INFANRIX DTPa vaccine is a sterile suspension which contains diphtheria toxoid, tetanus
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationBCCDC Measles, Mumps and Rubella Enhanced Surveillance Case Report Form
A. PERSON REPTING Disease: Measles Mumps Rubella INSTRUCTIONS Report cases of Measles, Mumps and/or Rubella to your MHO that meet suspect, probable/clinical or confirmed case definitions. Enter cases into
More informationABACAVIR HYPERSENSITIVITY REACTION
ABACAVIR HYPERSENSITIVITY REACTION Key Risk Minimisation Points: Abacavir Hypersensitivity Reaction (HSR) Abacavir is associated with a risk for hypersensitivity reactions (HSR) characterised by fever
More informationNSW Annual Adverse Events Following Immunisation Report, 2009
NSW Annual Adverse Events Following Immunisation Report, 2009 Deepika Mahajan A,D, Sue Campbell-Lloyd B, Ilnaz Roomiani C and Robert I. Menzies A A National Centre for Immunisation Research and Surveillance,
More informationSuspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine
Suspected Adverse Reaction Analysis CERVARIX Human papillomavirus (HPV) vaccine 2 May 2009 This report summarises the adverse reactions suspected to have been caused by Cervarix human papillomavirus (HPV)
More informationANAPHYLAXIS Following Vaccination. A Severe Adverse Event. Developed for the Grampians Infection Control Group (GRICG) Version 2.
ANAPHYLAXIS Following Vaccination A Severe Adverse Event Developed for the Grampians Infection Control Group () Version 2.0:2014 Adverse Event Following Immunisation Adverse event following immunisation
More informationThis is risky. Rabies. Are you at risk?
This is risky. Rabies Are you at risk? Are you at risk of rabies? You are at risk if you are in contact with potentially rabid animals: t Laboratory workers, veterinarians t Animal control workers, animal
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:
Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension
More informationPost vaccination febrile seizures: Clinical severity and outcome data is reassuring
Post vaccination febrile seizures: Clinical severity and outcome data is reassuring Dr Lucy Deng On behalf of Kristine Macartney, Nigel Crawford, Jim Buttery, Michael Gold, Peter Richmond and Nicholas
More informationBOOSTRIX -IPV PRODUCT INFORMATION. BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine.
BOOSTRIX -IPV PRODUCT INFORMATION NAME OF THE MEDICINE BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine. DESCRIPTION BOOSTRIX-IPV is a sterile
More informationVACCINE-RELATED ALLERGIC REACTIONS
VACCINE-RELATED ALLERGIC REACTIONS Management of Anaphylaxis IERHA Immunization Program September 2016 VACCINE-RELATED ADVERSE EVENTS Local reactions pain, edema, erythema Systemic reactions fever, lymphadenopathy
More informationBOOSTRIX PRODUCT INFORMATION
BOOSTRIX PRODUCT INFORMATION NAME OF THE MEDICINE Combined diphtheria-tetanus-acellular pertussis (dtpa) vaccine DESCRIPTION BOOSTRIX dtpa vaccine is a sterile suspension which contains diphtheria toxoid,
More informationInfection Control Guidance
Infection Control Guidance Links to Key Legislation and Guidance Children Act 1989 and 2004 United Nations Convention on the rights of the child 1989 Every Child Matters 2004 Early years Foundation Stage
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationpatient group direction
ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationPackage leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride
Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationHIBERIX PRODUCT INFORMATION
HIBERIX PRODUCT INFORMATION NAME OF THE MEDICINE HIBERIX Haemophilus influenzae type b (Hib) vaccine DESCRIPTION Powder and diluent for solution for injection. After reconstitution, 1 dose (0.5 ml) contains:
More informationCarboplatin / Gemcitabine Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously
More informationPackage leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride
Package leaflet: Information for the patient Cetirizin Sandoz 10 mg film-coated tablets cetirizine dihydrochloride [For medicine available only on prescription:] Read all of this leaflet carefully before
More informationBOOSTRIX POLIO. 3. PHARMACEUTICAL FORM Suspension for injection.
BOOSTRIX POLIO 1. NAME OF THE MEDICINAL PRODUCT boostrix polio Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) 2. QUALITATIVE
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCarboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed
More informationPATIENT INFORMATION LEAFLET
PPM Code: E1981 PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S2 PROPRIETARY NAME DOSAGE FORM: film coated tablets Read all of this leaflet carefully because it contains important information for you.
More information301 W. Alder, Missoula, MT or
301 W. Alder, Missoula, MT 59802 406-258-4745 or 406-258-3363 Routine Immunizations are available on a walk-in basis: Mondays, Tuesdays, Thursdays, and Fridays from 9:00am to 4:30pm Wednesdays, 10:00am-4:30pm
More informationMEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations.
Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic
More informationAnaphylaxis: Treatment in the Community
: Treatment in the Community is likely if a patient who, within minutes of exposure to a trigger (allergen), develops a sudden illness with rapidly progressing skin changes and life-threatening airway
More informationANALYSIS OF SCHEDULED VACCINES BOX INFORMATION INSERT
ANALYSIS OF SCHEDULED VACCINES BOX INFORMATION INSERT By Ricardo Beas July 4, 2015 (Rev. 7/10/2016) Full or partial reproduction of this document is authorized to all Below is the list of the 12 recommended
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Summary of Product Characteristics Meningitec suspension for injection in pre-filled syringe Meningococcal serogroup C oligosaccharide conjugate vaccine (adsorbed). 2 QUALITATIVE
More informationAnaphylaxis: treatment in the community
: treatment in the community Item Type Guideline Authors Health Service Executive Citation Health Service Executive. : treatment in the community. Dublin: Health Service Executive;. 5p. Publisher Health
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory INFANRIX Diphtheria Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. 1. NAME OF THE MEDICINAL PRODUCT
More informationANAPHYLAXIS. Following Vaccination of Adults. A Severe Adverse Event
ANAPHYLAXIS Following Vaccination of Adults A Severe Adverse Event Developed for the Grampians Infection Control Group () Version 3.0:2018 Target audience This information package is for nurse immunisers
More informationInfanrix TM Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa) vaccine
Infanrix TM Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa) vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION Infanrix TM contains diphtheria toxoid, tetanus toxoid and three purified
More informationPeriodic Fever With Apthous Pharyngitis Adenitis (PFAPA)
www.printo.it/pediatric-rheumatology/za_gb/intro Periodic Fever With Apthous Pharyngitis Adenitis (PFAPA) Version of 2016 1. WHAT IS PFAPA 1.1 What is it? PFAPA stands for Periodic Fever Adenitis Pharyngitis
More informationPatient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine
n Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine October 2009 PGD version template-2009.1 Page 1 of 8 Rationale Patient Group Direction For The Administration Of H1N1 (Swine
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDatabase of Adverse Event Notifications - medicines
Database of Adverse Event Notifications - medicines You searched for the following 3 medicines between 01/01/2017 01/01/2018: Ferinject 100mg/2mL (Ferric carboxymaltose) Ferinject 500mg/10mL (Ferric carboxymaltose)
More informationINFANRIX IPV PRODUCT INFORMATION
INFANRIX IPV PRODUCT INFORMATION NAME OF THE MEDICINE INFANRIX IPV vaccine is a combined diphtheria, tetanus, acellular pertussis (DTPa) and inactivated poliovirus vaccine. DESCRIPTION INFANRIX IPV vaccine
More informationMast Cell Activation Syndrome
Mast Cell Activation Syndrome Clinical Questionnaire Description Today s Date: Patient Name: Please indicate yes or no for the following symptoms and traits: (If you are not familiar with a particular
More informationVACCINE-RELATED ALLERGIC REACTIONS
VACCINE-RELATED ALLERGIC REACTIONS Management of Anaphylaxis Public Health Immunization Program June 2018 VACCINE-RELATED ADVERSE EVENTS Local reactions pain, edema, erythema Systemic reactions fever,
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationImmunizations Offered
Immunizations Offered Most vaccines commercially available in the United States are available at the health clinic. A partial list of available vaccines follows. For more information about specific vaccines
More informationPEDIACEL. Intramuscular injection. Suspension for injection. DESCRIPTION
PEDIACEL Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine and Haemophilus b Conjugate Vaccine (Tetanus Protein - Conjugate) Intramuscular
More informationSeasonal Influenza in Alberta 2010/2011 Summary Report
Seasonal Influenza in Alberta 21/211 Summary Report Government of Alberta October 211 ISSN 1927-4114, Surveillance and Assessment Branch Send inquiries to: Health.Surveillance@gov.ab.ca Executive Summary
More informationPackage leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride
Package leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it
More informationMEASLES, MUMPS, RUBELLA (MMR)
MEASLES, MUMPS, RUBELLA (MMR) WHAT YOU NEED TO KNOW ARE YOU SURE YOU USE THE RIGHT MEASURES TO PROTECT YOURSELF AGAINST MEASLES, MUMPS OR RUBELLA? GET INFORMED! GET VACCINATED! GET PROTECTED! MMR VACCINE
More informationMethotrexate. About This Drug. Possible Side Effects. Warnings and Precautions
Methotrexate About This Drug Methotrexate is used to treat cancer. This drug is given in the vein (IV). Possible Side Effects Soreness of the mouth and throat. You may have red areas, white patches, or
More information+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -
Review of Systems: 0-1 year old Constitution neg Eyes neg GI neg Neurological neg + Activity Change - + Eye Discharge - + Reflux - + Facial Asymmetry - + Appetite Change - + Eye Redness - + Vomiting -
More information1. QUALITATIVE AND QUANTITATIVE COMPOSITION
INFANRIX 1. QUALITATIVE AND QUANTITATIVE COMPOSITION contains diphtheria toxoid, tetanus toxoid, and three purified pertussis antigens [pertussis toxoid (PT), filamentous haemagglutinin (FHA) and 69 kilodalton
More informationHelp protect your child. At-a-glance guide to childhood vaccines.
Help protect your child. At-a-glance guide to childhood vaccines. Why vaccines matter. Thanks to widespread vaccination programs, several diseases that can infect our children have been eliminated. But
More informationINFANRIX-IPV Product Information 1(13) INFANRIX IPV
INFANRIX-IPV Product Information 1(13) INFANRIX IPV NAME OF THE DRUG INFANRIX IPV vaccine is a combined diphtheria, tetanus, acellular pertussis (DTPa) and inactivated poliovirus vaccine. DESCRIPTION INFANRIX
More informationHelp protect your child. At-a-glance guide to childhood vaccines.
Help protect your child. At-a-glance guide to childhood vaccines. Why vaccines matter. Thanks to widespread vaccination programs, several diseases that can infect our children have been eliminated. But
More informationPriorix TM Measles, mumps and rubella vaccine (live, attenuated)
Priorix TM Measles, mumps and rubella vaccine (live, attenuated) QUALITATIVE AND QUANTITATIVE COMPOSITION Priorix is a lyophilised mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived
More information1.1. An overview of reports on sitagliptin
1.1. An overview of reports on Introduction Sitagliptin (Januvia ) was registered for the European marked on March 21 st 27 with the Netherlands as rapporteur. It is indicated as treatment of for patients
More informationPackage leaflet: Information for the user Zirtek Allergy Relief 10 mg Film Coated Tablets Cetirizine dihydrochloride
Package leaflet: Information for the user Zirtek Allergy Relief 10 mg Film Coated Tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it
More informationPackage leaflet: Information for the user Zirtek Allergy Relief for Children 1 mg/ml Oral Solution Cetirizine dihydrochloride
Package leaflet: Information for the user Zirtek Allergy Relief for Children 1 mg/ml Oral Solution Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX Haemophilus type b conjugated vaccine IP 1. NAME OF THE MEDICINAL PRODUCT Haemophilus type b conjugated vaccine
More informationTABLE OF CONTENTS. In what way can this educational material help me? Why are vaccinations important? Who needs vaccinations?
www.promovax.eu TABLE OF CONTENTS A B C D E F G H In what way can this educational material help me? Why are vaccinations important? Who needs vaccinations? Which diseases do vaccines prevent? Are vaccinations
More informationGardasil Network Development Project GARDASIL VACCINE QUESTIONNAIRE
Questionnaire ID Gardasil Network Development Project GARDASIL VACCINE QUESTIONNAIRE Answering this questionnaire is voluntary. Personal identifying information will not be shared with anyone outside of
More informationLocal Omalizumab Treatment Protocol (For children 6 to <12 years of age)
Local Omalizumab Treatment Protocol (For children 6 to
More informationBlood Transfusion Reactions
Blood Transfusion Reactions Introduction Many individuals require blood components and blood products. As per the BC Transfusion Medicine Advisory Group (BCTMAG), a blood component is at therapeutic component
More informationMODEL INSERT MEASLES, MUMPS AND RUBELLA (MMR) COMBINED VACCINE
MODEL INSERT MEASLES, MUMPS AND RUBELLA (MMR) COMBINED VACCINE DESCRIPTION The vaccine is a freeze-dried powder containing three viruses - measles, mumps and rubella. a) The measles vaccine component is
More informationADT Booster Data Sheet
1. PRODUCT NAME ADT Booster. Diphtheria and Tetanus Vaccine (adsorbed) for revaccination. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ADT Booster is a suspension for intramuscular injection, containing
More informationWest Nile Fever. F. Karup Pedersen 2012
F. Karup Pedersen 2012 West Nile virus first isolated 1937 in West Nile district, Uganda Japanese encephalitis reconvalescens serum could neutralize West Nile virus Virus antigenically related to Japanese
More informationAUSTRALIAN PRODUCT INFORMATION
AUSTRALIAN PRODUCT INFORMATION NAME OF THE MEDICINE QUADRACEL Pertussis Vaccine-Acellular and Diphtheria and Tetanus Toxoids (Adsorbed) Combined with Inactivated Poliovirus Types 1, 2 and 3 (MRC-5 Cell).
More informationDiphtheria, Tetanus, and Pertussis. DTaP/DT and Tdap/Td Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Diphtheria, Tetanus, and Pertussis DTaP/DT and Tdap/Td Vaccines Jean C. Smith, MD, MPH Medical Officer
More informationADT Booster Product Information
NAME OF THE MEDICINE ADT Booster. Diphtheria and Tetanus Vaccine (adsorbed) for revaccination. DESCRIPTION ADT Booster is a suspension for intramuscular injection, containing aluminium-hydroxide-adsorbed
More informationHelp protect your child. At-a-glance guide to childhood vaccines.
Help protect your child. At-a-glance guide to childhood vaccines. 40976_CDCupdate.indd 1 Why vaccines matter. Thanks to widespread vaccination programs, several diseases that can infect our children have
More informationPackage Leaflet: Information for the user. Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)
Package Leaflet: Information for the user Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed) Read all of this leaflet carefully before you or your
More informationDrug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment
Drug Resistant Tuberculosis Self-reporting of Drugrelated Adverse Events During Treatment Introduction This information has been prepared for people with tuberculosis (TB) that is resistant to the commonly
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationCOMPOSITION OF VACCINE per 1 ml: not less than 30 OU/ml (not less than 8.0 IU/ml)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 QUINVAXEM in cpad DTwP HepB Hib fully liquid combination vaccine DESCRIPTION The vaccine is a homogeneous
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationAUSTRALIAN PRODUCT INFORMATION
AUSTRALIAN PRODUCT INFORMATION NAME OF THE MEDICINE IMOJEV Japanese encephalitis vaccine (live, attenuated) DESCRIPTION IMOJEV is a monovalent, live attenuated viral vaccine. The virus was obtained via
More informationMEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia.
ALL REPORT DATES Causality Unclear Excluded Total Death Outcome Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME NEW ZEALAND DATA SHEET HIBERIX Haemophilus influenzae type b (Hib) powder and diluent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationDANISH PHARMACOVIGILANCE UPDATE
NO. 8 VOLUME 6 SEPTEMBER 2015 News from the EU Contents Mirabegron (Betmiga): New recommendations regarding the risk of increase in blood pressure 2 News from the DHMA Childhood vaccinations and reported
More informationViral Vaccines I 5/17/04 LECTURE OUTLINE I. CASE HISTORY
Viral Vaccines I I. CASE HISTORY LECTURE OUTLINE 5/17/04 A 22-year-old Amish woman became ill with a headache, fever, and generalized muscle pain. Two days later, she developed right and then left lower
More informationPharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:
0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology
More information